MEDICINA
Departamento
Eli Lilly and Company
Indianapolis, EE. UU.Publicaciones en colaboración con investigadores/as de Eli Lilly and Company (6)
2023
-
Real-World Persistence and Treatment Patterns in Patients with Psoriatic Arthritis Treated with Anti-IL17 Therapy in Spain: The PerfIL-17 Study
Advances in Therapy, Vol. 40, Núm. 12, pp. 5415-5431
2022
-
Adjuvant abemaciclib combined with endocrine therapy for high-risk early breast cancer: safety and patient-reported outcomes from the monarchE study
Annals of oncology : official journal of the European Society for Medical Oncology, Vol. 33, Núm. 6, pp. 616-627
2021
-
Integrative Analysis Reveals a Molecular Stratification of Systemic Autoimmune Diseases
Arthritis and Rheumatology, Vol. 73, Núm. 6, pp. 1073-1085
2008
-
Effect of raloxifene after recombinant teriparatide [hPTH(1-34)] treatment in postmenopausal women with osteoporosis
Osteoporosis International, Vol. 19, Núm. 1, pp. 87-94
2004
-
Continuing outcomes relevant to Evista: Breast cancer incidence in postmenopausal osteoporotic women in a randomized trial of raloxifene
Journal of the National Cancer Institute, Vol. 96, Núm. 23, pp. 1751-1761
2003
-
A randomized, double-blind, placebo-controlled, clinical trial of the effects of pioglitazone on glycemic control and dyslipidemia in oral antihyperglycemic medication-naive patients with type 2 diabetes mellitus
Clinical Therapeutics, Vol. 25, Núm. 4, pp. 1074-1095